Novel C5α-substituted carbapenems enhance Mycobacterium abscessus killing via selective target binding and reduced hydrolysis by Bla Mab
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00170-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Eunjeong Shin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Carbapenems, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Mycobacterium abscessus ( Mab ) poses significant clinical challenges and underscores the urgent need for safer and more effective treatments, including β-lactams. Among currently available carbapenems, imipenem is widely used to treat Mab infections by combining with other antibiotics. Commercial carbapenems share a common scaffold with C2 modifications, whereas this study focuses on novel carbapenem candidates with C5α modifications. We evaluated their antibacterial activity against Mab ATCC 19977 and clinical isolates, as well as their acylation of peptidoglycan target receptors (L,D-transpeptidases [LDTs] and penicillin-binding proteins [PBPs]) and the β-lactamase enzyme Bla Mab . In vitro studies of two C5α-modified carbapenems, JDB/NA-1-157 and JDB/NA-1-208, revealed distinct antibacterial effects. JDB/NA-1-157 demonstrated potent bacterial killing with low minimum inhibitory concentrations (MICs; 0.125–8 mg/L) and near-complete eradication within 5 days, surpassing the efficacy of the standard-of-care regimen (amikacin + clarithromycin + imipenem). In contrast, JDB/NA-1-208 exhibited poor bacterial killing, with high MICs (16–256 mg/L) and limited efficacy in time-kill studies. However, JDB/NA-1-208 showed synergistic killing when combined with other β-lactams. Mechanistically, JDB/NA-1-208 is not a substrate for Bla Mab , while JDB/NA-1-157 is, albeit with low catalytic efficiency. This is supported by the observation that the addition of avibactam did not enhance synergy with JDB/NA-1-157. The substantial bacterial killing effect of JDB/NA-1-157 is attributed to its high binding affinity for PBP-B, PBP-lipo, PonA2, D,D-carboxypeptidase, and LDT1–2. These findings highlight the potential of novel C5α-modified carbapenems, particularly JDB/NA-1-157, as promising therapeutic candidates for Mab infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Chemistry, Southern Methodist University, Dallas, Texas, USA.
- Ohio State University, Columbus, Ohio, USA.
- Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Pediatrics, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.
ORCID-Profile: Eunjeong Shin, Khalid M Dousa, Eric J Rubin, Barry N Kreiswirth, John D Buynak, Robert A Bonomo
Förderung
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- Cystic Fibrosis Foundation
Zitieren
APA
Shin, E., Taracila, M. A., Quan, P., Khan, M. M. K., Cox, J., Patel, D., Dousa, K. M., Parmar, A., Nantongo, M., Nguyen, D. C., Rubin, E. J., Holland, S. M., Kreiswirth, B. N., Buynak, J. D., & Bonomo, R. A. (2025). Novel C5α-substituted carbapenems enhance Mycobacterium abscessus killing via selective target binding and reduced hydrolysis by Bla Mab. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00170-25
Vancouver
Shin E, Taracila MA, Quan P, Khan MMK, Cox J, Patel D, et al. Novel C5α-substituted carbapenems enhance Mycobacterium abscessus killing via selective target binding and reduced hydrolysis by Bla Mab. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00170-25
BibTeX
@article{Shin2025,
author = {Shin, Eunjeong and Taracila, Magdalena A and Quan, Pojun and Khan, Md Mahbub Kabir and Cox, Jonathan and Patel, Diya and Dousa, Khalid M and Parmar, Aetan and Nantongo, Mary and Nguyen, David C and Rubin, Eric J and Holland, Steven M and Kreiswirth, Barry N and Buynak, John D and Bonomo, Robert A},
title = {Novel C5α-substituted carbapenems enhance Mycobacterium abscessus killing via selective target binding and reduced hydrolysis by Bla Mab},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00170-25}
}
EUVIMED